Phase 1 Study Evaluating Safety and Tolerability of Medi4736, an Anti-Programmed Cell Death Ligand-1 (Pd-L1) Antibody, in Combination with Dabrafenib and Trametinib or Trametinib Alone in Patients with Unresectable or Metastatic Melanoma

Category Primary study
JournalAnnals of Oncology
Year 2014
This article has no abstract
Epistemonikos ID: db0721ee42b12cf601812906239f768131babf41
First added on: Feb 19, 2025